Whats new on the horizon for rheumatoid arthritis management Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy
Unlocking the Future: New Biologic Therapies for Rheumatoid . . . In the present review, we discuss the potential of emerging RA biologic therapy centered on RASF (rheumatoid arthritis synovial fibroblasts) triggering molecules, B cell activating factor (BAFF), a protein of the tumor necrosis factor (TNF) family, and alarmins S100 calcium-binding protein A7 (S100A7, also known as psoriasin) and IL-36α in the
EULAR Updates Recommendations for Managing RA - Medscape BARCELONA, Spain — Patients with rheumatoid arthritis (RA) who have not responded to first-line methotrexate therapy should be started on a biologic or targeted synthetic disease-modifying
Whats new on the horizon for rheumatoid arthritis management Rheumatoid arthritis (RA) is a chronic multisystem common autoimmune disease Joints and the whole musculoskeletal system bear the brunt of the disease Proper adequate treatment at the early stage is the foremost necessity to protect the patients from long term disabilities and reduce patient syste …
Breakthrough Rheumatology Trends and Innovations for 2025 Findings will be discussed in a full report to be published by the AAMC in early 2025 2025 Promising Trends and Breakthroughs Looking ahead, 2025 promises even more exciting innovations: 1 AI and Medicine Artificial intelligence (AI) is poised to revolutionize the way rheumatologists diagnose and treat patients By analyzing vast amounts of